Skip to main content

News & Events


New Publication Further Validates SeptiCyte® RAPID for Disease Severity Assessment and Triaging in COVID-19 Patients with Extensive Lung Injury

March 21, 2023
A study in the journal Viruses validates the use of SeptiCyte® RAPID as a tool to measure disease severity in COVID-19 patients, in comparison to a reference method based on chest computed tomography (CT) imaging.

New Publication Validates SeptiCyte® RAPID as a Triaging Tool for COVID-19 Patients

February 3, 2023
A new study in Scientific Reports, a journal in the Nature portfolio, validates the use of SeptiCyte® RAPID as a triaging tool for COVID-19 patients requiring hospitalization and potentially ICU care.

Immunexpress Begins US Commercialization of Near-Patient Sepsis Diagnostic Test

February 3, 2023
This article about Immunexpress and its sepsis diagnostic test was published in GenomeWeb.

At AMP 2022, Immunexpress launches rapid test for sepsis requiring two minutes hands-on time

November 10, 2022
At the Association for Molecular Pathology annual meeting and exposition this week, Immunexpress launched a rapid molecular diagnostic test that could enable ruling in or ruling out sepsis in one hour.

Multi-site study confirms the use of undiluted EDTA blood for the SeptiCyte RAPID sepsis assay

November 10, 2022
Data Validating EDTA Blood as Sample Type for SeptiCyte® RAPID Presented at the Association for Molecular Pathology 2022 Annual Meeting

Dr. Rollie Carlson, CEO, Immunexpress: Providing RAPID Detection for Sepsis

October 24, 2022
DocWire News spoke with Dr. Rollie Carlson, CEO of Immunexpress, to learn more about this cutting-edge technology, and how it can quickly and accurately detect sepsis, and lead to faster treatment.

Building a powerful portfolio of sepsis biomarker signatures for therapeutic clinical trials

October 21, 2022
In this Q&A, Immunexpress Chief Executive Officer Dr Rolland Carlson and Chief Scientific Officer Dr Richard Brandon discuss key aspects for molecular diagnostic discovery and development platforms, including how to best leverage microarray and next-generation sequencing (NGS) tools.
identification of pathogens

Immunexpress Announces the Launch of New SeptiCyte RAPID® CE-IVD EDTA Blood Compatible Cartridges

October 1, 2022
SeptiCyte® RAPID EDTA blood compatible cartridges were recently launched in the European market, representing a significant development milestone for the identification of pathogens associated with sepsis. This press release and the associated blog posts explore the significance of this development.
sepsis diagnosis

A Paradigm Shift In Diagnosing Sepsis

September 30, 2022
This article from Technology Networks includes an interview with Rolland Carlson, PhD, the CEO of Immunexpress. Rolland describes the paradigm shift in sepsis diagnosis as well as the specifics of how SeptiCyte® RAPID provides a faster and accurate diagnosis, allowing physicians to quickly rule-in or rule-out sepsis.

Tips For Obtaining Your 510(k) FDA Clearance

July 8, 2022
Learn more about the process of getting the lab test for sepsis, SeptiCyte® RAPID, cleared by the FDA. This article from Med Device Online also includes tips for obtaining a 510(k) FDA Clearance for other medical use products.

Data presented by Immunexpress collaborator from a study supporting SeptiCyte® RAPID performance for COVID-19 patient triage

April 19, 2022
At the 32nd ECCMID, Immunexpress and collaborators at Hospital Foch, France, shared research demonstrating that SeptiCyte® RAPID sepsis test can distinguish between COVID-19 patients showing higher extents of lung damage as defined by lung CT scans from those with a milder presentation.

Discussing Sepsis Diagnosis with Immunexpress

December 22, 2021
In this DNA Weekly interview, Immunexpress CEO Dr. Rollie Carlson, discusses why the company is tackling sepsis, explains the challenge of diagnosing sepsis, and details how SeptiCyte® RAPID helps. He also discusses how SeptiCyte® RAPID allows hospital systems to improve their sepsis management quality scores.

Immunexpress’ rapid sepsis test receives FDA clearance

December 9, 2021
Often difficult to diagnosis, sepsis remains a leading cause of morbidity and mortality among intensive care unit (ICU) patients. SeptiCyte® RAPID is the first FDA-cleared sepsis diagnostic to differentiate sepsis from non-infectious systemic inflammation to aid in rapid sepsis diagnosis within approximately one hour.

FDA grants 510(k) clearance for Immunexpress’ SeptiCyte RAPID test

December 1, 2021
This Medical Device Network article highlights our FDA-cleared sepsis diagnostic SeptiCyte® RAPID. The fast sepsis test addresses “a critically unmet need in the ICU,” said Immunexpress Chief Medical Officer, Dr. Roy Davis. SeptiCyte® technology aids physicians in distinguishing sepsis from -infection-negative (SIRS) systemic inflammation in critically ill patients.

10 News Brisbane – Device That Can Save Lives from Sepsis Awaiting Australian Regulatory Approval

September 15, 2021
In this interview with 10 News Brisbane, Dr. Adam Irwin, physician, and senior lecturer of pediatric infectious disease at the University of Queensland, details how deadly a sepsis diagnosis can be for children. Richard Brandon, Chief Scientific Officer of Immunexpress, shares the development of a one-hour sepsis test, SeptiCyte® RAPID, that is awaiting Australian regulatory approval.

SeptiCyte® RAPID proved superior sepsis diagnostic compared to lactate and procalcitonin

September 14, 2021
SeptiCyte® RAPID is a sepsis test that uses peripheral blood gene expression biomarkers to provide accurate sepsis diagnosis in patients presenting with clinical signs of systemic inflammation. Data was presented detailing the superior performance of SeptiCyte® RAPID in differentiating sepsis from non-infectious inflammatory responses at the 2021 IDWeek Conference.